Kuehn Law Encourages DSKE, RYZB, ROVR, and GRPH Investors to Contact Law Firm Kuehn Law investigates DSKE, RYZB, ROVR, GRPH mergers for shareholder rights, seeking fair process and disclosures.

RYZB News: Johnson Fistel Investigates Proposed Sale of RayzeBio; Is $62.50 a Fair Price? On December 26, 2023, RayzeBio announced that it had entered a deal with Bristol Myers Squibb.

Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio Transaction Brings RayzeBio’s Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs to Bristol Myers Squibb’s Leading Oncology...

RayzeBio Appoints Industry Leader Tim Van Hauwermeiren to Its Board of Directors SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today...